NASDAQ:CPAH - CounterPath Stock Price, Forecast & News

CounterPath trades on the NASDAQ under the ticker symbol "CPAH."

CounterPath, Corp. (NASDAQ:CPAH) released its quarterly earnings data on Wednesday, December, 11th. The software maker reported ($0.13) EPS for the quarter. The software maker had revenue of $2.70 million for the quarter. CounterPath had a negative return on equity of 119.27% and a negative net margin of 34.26%. View CounterPath's Earnings History.

CounterPath is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for CounterPath.

News coverage about CPAH stock has been trending extremely negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CounterPath earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned media coverage about the software maker a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for CounterPath.

CounterPath saw a decline in short interest during the month of January. As of January 15th, there was short interest totalling 61,300 shares, a decline of 22.1% from the December 31st total of 78,700 shares. Based on an average trading volume of 997,900 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.2% of the company's shares are short sold. View CounterPath's Current Options Chain.

Some companies that are related to CounterPath include ImageWare Systems (IWSY), CLPS (CLPS), NetSol Technologies (NTWK), Astea International (ATEA), Audioeye (AEYE), Gridsum (GSUM), Qumu (QUMU), Taoping (TAOP), FORESIGHT AUTON/S (FRSX), FalconStor Software (FALCD), FalconStor Software (FALC), Rego Payment Architectures (RPMT), Validian (VLDI), BroadVision (BVSN) and Destiny Media Technologies (DSNY).

Based on aggregate information from My MarketBeat watchlists, some companies that other CounterPath investors own include Inpixon (INPX), Sierra Oncology (SRRA), Biocept (BIOC), Tonix Pharmaceuticals (TNXP), FuelCell Energy (FCEL), Kopin (KOPN), Actinium Pharmaceuticals (ATNM), Pharmacyte Biotech (PMCB), SANUWAVE Health (SNWV) and Athersys (ATHX).

CounterPath's stock is owned by a number of of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.99%). Company insiders that own CounterPath stock include Larry Timlick and Steven Bruk. View Institutional Ownership Trends for CounterPath.

CPAH stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for CounterPath.

Shares of CPAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CPAH stock can currently be purchased for approximately $2.09.

CounterPath has a market capitalization of $12.46 million and generates $10.77 million in revenue each year. CounterPath employs 98 workers across the globe.View Additional Information About CounterPath.

The official website for CounterPath is http://www.counterpath.com/.

CounterPath's mailing address is 300-505 BURRARD STREET, VANCOUVER A1, V7X 1M3. The software maker can be reached via phone at 604-320-3344 or via email at [email protected]